Mao Shuai, Xu Dan-Ping, Dang Xiao-Jing, Li Winny, Wu Huan-Lin
Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Heart Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.
Chin J Integr Med. 2019 Feb;25(2):96-102. doi: 10.1007/s11655-018-3017-z. Epub 2018 Oct 17.
Many patients with chronic angina experience anginal episodes despite successful recanalization, antianginal and antiischemic medications. Empirical observations suggested that Shenzhu Guanxin Recipe Granules (, SGR), a Chinese herbal compound, exerted potential impacts on increased treadmill exercise performance and angina relieve. However, there has been no systematic study to clarify the impact of SGR on exercise tolerance in patients with stable angina. The SERIES (ShEnzhu guanxin Recipe for Improving Exercise tolerance in patients with Stable angina) trial is designed to determine the effects of SGR on exercise duration, electrocardiographic (ECG) evidence of myocardial ischemia, and incidence of major adverse cardiac events (MACE) in stable anginal patients.
A total of 184 eligible patients with stable angina will be randomly assigned to receive placebo or SGR (10 g/day for 12 weeks) in a 1:1 ratio. The primary outcome will be the change from baseline in total exercise tolerance duration, time to onset of angina and ECG ischemia during exercise treadmill testing performed over a 12-week study period. The secondary outcome will include ECG measures, the occurrence and composite of MACE and the Seattle Angina Questionnaire score. Moreover, the coronary microcirculation will be evaluated to explore the possible effects in response to treatment of SGR. After the procedure, all participants will be followed up by interview at 3 and 6 months, enquiring about any cardiac events, hospitalizations, cardiac functional level and medication usage. Additionally, the occurrence of adverse events will be evaluated at each follow-up.
This study may provide novel evidence on the efficacy of SGR in improving exercise tolerance and potentially reducing clinical adverse events. (Trial registration No. ChiCTR-TRC-14004504).
许多慢性心绞痛患者尽管成功进行了血管再通、服用了抗心绞痛和抗缺血药物,但仍会出现心绞痛发作。经验观察表明,中药复方参术冠心颗粒(SGR)对提高跑步机运动表现和缓解心绞痛有潜在影响。然而,尚未有系统研究阐明SGR对稳定型心绞痛患者运动耐量的影响。SERIES(参术冠心方改善稳定型心绞痛患者运动耐量)试验旨在确定SGR对稳定型心绞痛患者运动持续时间、心肌缺血的心电图(ECG)证据以及主要不良心脏事件(MACE)发生率的影响。
总共184例符合条件的稳定型心绞痛患者将按1:1的比例随机分配接受安慰剂或SGR(10克/天,共12周)。主要结局将是在为期12周的研究期间进行的运动跑步机测试中,总运动耐量持续时间、心绞痛发作时间和运动期间ECG缺血从基线的变化。次要结局将包括ECG测量、MACE的发生情况和综合情况以及西雅图心绞痛问卷评分。此外,将评估冠状动脉微循环,以探索对SGR治疗的可能反应。试验结束后,所有参与者将在3个月和6个月时接受随访访谈,询问任何心脏事件、住院情况、心功能水平和药物使用情况。此外,每次随访时将评估不良事件的发生情况。
本研究可能为SGR在改善运动耐量和潜在减少临床不良事件方面的疗效提供新证据。(试验注册号:ChiCTR-TRC-14004504)